Rayvio_News_Filter
$ELOX 🏥
Eloxx Pharmaceuticals announced publication in the Journal of Clinical Investigation of Phase 2a proof-of-mechanism data showing exaluren was well tolerated and increased collagen IV abundance in all three patients with nonsense mutation Alport syndrome.
Timely market event